By now, you probably know the pap tests aren’t a magic wand that’ll save you from cancer.
The tests have been used for years to detect breast cancer, ovarian cancer, cervical cancer, rectal cancer, and a host of other diseases, but they’ve been criticized for not having as much predictive power as a genetic test.
Now, scientists are looking into new technologies to improve Pap tests’ accuracy and efficiency.
The Pap test is a blood test that detects abnormal cells, and is considered the gold standard of health care for detecting cancer.
If a person has cancer, it’s often due to an abnormal cell in the cervix that can trigger cancerous cells to multiply and invade the uterus and/or other parts of the body.
It’s also the test that many people test for and are told to have done every year for years on end.
But scientists have been studying ways to improve the Pap test’s accuracy and effectiveness over the past few years, and the answer to the question, “Does it work?” has been a resounding no.
“I think that is a real debate and a real discussion and it’s been ongoing for a long time,” said Dr. Jennifer Matson, an infectious disease expert and director of the Center for Cellular and Molecular Immunology at Columbia University.
In 2014, Matson and her colleagues published a paper in the journal Cell pointing to a new way of improving Pap test accuracy that would allow them to predict more accurately whether a person is at increased risk for certain cancers.
It’s the latest study to challenge the validity of the tests, but it’s the first to look at a specific way of speeding up the test’s detection rate, and finding a way to improve on its reliability and accuracy.
“It’s a real question mark,” Matson said.
“What are the things that we can do to improve accuracy?”
Scientists are looking to improve what’s known as the ‘thin prep’ method, which uses the thin membranes of a cell to make the Pap tests much more accurate.
That means they can pick up the abnormal cells faster and find them earlier in the screening process.
“That is one of the most important things,” Mckenzie said.
To improve the test, scientists have found ways to use different types of proteins, called antibodies, in the Pap and other tests, or to use more specific proteins in the thin prep test, called protein-based antibodies.
Matson is currently testing for protein-protein interactions, which are proteins that bind to different proteins on the surface of cells.
If the antibodies bind to a specific protein, it can then help the test determine the presence of cancerous cell in a person.
“The more we know about protein interactions, the better we can make the test,” Mackenzie said, adding that it will take about three years to determine whether protein-pharmaceuticals could improve Pap testing accuracy.
Matson’s research has also looked at the possibility of using a drug that boosts the proteins that are found in the test.
If that drug works, Mckettys hope that the drug could reduce the risk of Pap tests being misread, making the test less accurate.
“One of the things we have done is to look into different ways to enhance the test and the amount of antibodies it uses,” M Mackenzie said and added that it was possible that antibodies could be incorporated into the test itself, rather than being in a thin prep product.
Another promising way of enhancing Pap test detection is using a technique called immunoassay to determine the number of cells in a test specimen.
Scientists at the National Institutes of Health are developing an immunoaccuracy test that uses antibodies to identify the cells in an immunological test, and then compares that to the number found in an ordinary blood test.
In their study, researchers found that an antibody test could be used to accurately determine the level of cancer in an individual.
It’s not clear if this method will be a reality anytime soon, but researchers are working to figure out how to optimize the test for use in patients, as well as testing other patients to see how it works in their situations.
Researchers also hope to see improvements in the technology that will allow them more accurate tests.
There are two main types of Pap test.
The thin prep version is called a “thin screen” and it detects abnormal blood cells in the womb, while the normal pap test is called the “normal screen.”
Both tests are performed in the same laboratory, and are then sent off to a lab for further testing.
Researchers are also studying how the thinner screen will improve Pap test reliability.
Dr. Andrew B. Burt, an associate professor at the University of Minnesota, has been testing the thin screen in the lab for several years and has seen a lot of positive results.
Burt is also an expert in protein-polymerase chain reaction, or PPCR